Anavex Life Sciences Corp. (NASDAQ:AVXL) Receives Average Recommendation of “Hold” from Analysts

Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) have been assigned an average rating of “Hold” from the five ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $21.3333.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Anavex Life Sciences in a research report on Tuesday.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of AVXL. State of Wyoming acquired a new stake in shares of Anavex Life Sciences during the 2nd quarter valued at $26,000. Yukon Wealth Management Inc. bought a new stake in Anavex Life Sciences during the 2nd quarter worth $36,000. Quarry LP acquired a new position in Anavex Life Sciences in the 3rd quarter worth about $36,000. Baird Financial Group Inc. acquired a new position in Anavex Life Sciences in the 2nd quarter worth about $40,000. Finally, Advisory Alpha LLC bought a new position in Anavex Life Sciences in the fourth quarter valued at about $44,000. 31.55% of the stock is currently owned by institutional investors and hedge funds.

Anavex Life Sciences Stock Performance

Shares of AVXL opened at $2.62 on Friday. Anavex Life Sciences has a 52-week low of $2.26 and a 52-week high of $10.38. The business’s fifty day moving average is $2.87 and its 200-day moving average is $3.15. The firm has a market cap of $242.87 million, a price-to-earnings ratio of -17.47 and a beta of 1.14.

Anavex Life Sciences (NASDAQ:AVXL) last issued its earnings results on Tuesday, August 25th. The biotechnology company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.16.

About Anavex Life Sciences

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.